AR-15512 shows promise in treating dry eye disease in Phase 3 studies

AR-15512, a selective TRPM8 agonist, has shown strong efficacy in increasing tear production and improving symptoms in patients with dry eye disease (DED) in two Phase 3 clinical trials, according to a poster presented at the 2024 American Academy of Optometry Annual Meeting In these studies, AR-15512 was shown to...